NO20014537D0 - AKT-nukleinsyrer, -polypeptider og anvendelse av disse - Google Patents

AKT-nukleinsyrer, -polypeptider og anvendelse av disse

Info

Publication number
NO20014537D0
NO20014537D0 NO20014537A NO20014537A NO20014537D0 NO 20014537 D0 NO20014537 D0 NO 20014537D0 NO 20014537 A NO20014537 A NO 20014537A NO 20014537 A NO20014537 A NO 20014537A NO 20014537 D0 NO20014537 D0 NO 20014537D0
Authority
NO
Norway
Prior art keywords
polypeptides
nucleic acids
akt3
akt nucleic
relates
Prior art date
Application number
NO20014537A
Other languages
English (en)
Other versions
NO20014537L (no
Inventor
Kun Guo
Marco F Pagnoni
Kenneth L Clark
Yuri D Ivashchenko
Original Assignee
Aventis Pharm Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharm Prod Inc filed Critical Aventis Pharm Prod Inc
Publication of NO20014537D0 publication Critical patent/NO20014537D0/no
Publication of NO20014537L publication Critical patent/NO20014537L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
NO20014537A 1999-03-19 2001-09-18 AKT-nukleinsyrer, -polypeptider og anvendelse av disse NO20014537L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12510899P 1999-03-19 1999-03-19
PCT/US2000/006574 WO2000056866A2 (en) 1999-03-19 2000-03-14 Akt-3 nucleic acids, polypeptides, and uses thereof

Publications (2)

Publication Number Publication Date
NO20014537D0 true NO20014537D0 (no) 2001-09-18
NO20014537L NO20014537L (no) 2001-10-31

Family

ID=22418217

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20014537A NO20014537L (no) 1999-03-19 2001-09-18 AKT-nukleinsyrer, -polypeptider og anvendelse av disse

Country Status (18)

Country Link
EP (1) EP1144600B1 (no)
JP (1) JP4237945B2 (no)
KR (1) KR100700908B1 (no)
AT (1) ATE402995T1 (no)
AU (1) AU782448B2 (no)
BR (1) BR0009170A (no)
CA (1) CA2343074C (no)
CY (1) CY1108459T1 (no)
DE (1) DE60039677D1 (no)
DK (1) DK1144600T3 (no)
ES (1) ES2310515T3 (no)
HK (1) HK1041288B (no)
IL (4) IL141984A0 (no)
NO (1) NO20014537L (no)
PT (1) PT1144600E (no)
SI (1) SI1144600T1 (no)
WO (1) WO2000056866A2 (no)
ZA (1) ZA200108414B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881555B2 (en) 1999-03-19 2005-04-19 Aventis Pharmaceuticals Inc. AKT nucleic acids, polypeptides, and uses thereof
CZ20013427A3 (cs) 1999-04-16 2002-03-13 Yale University Izolovaná molekula nukleové kyseliny, izolovaný NOS polypeptid, způsob stimulace, způsob léčby a způsob identifikace a nehumánní transgenní zvíře
HUP0201663A3 (en) * 1999-06-11 2005-01-28 Gencell Inc Bridgewater Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt
JPWO2003063905A1 (ja) * 2002-01-31 2005-05-26 株式会社東京大学Ｔｌｏ 免疫疾患の予防又は治療剤
US10517883B2 (en) 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US20070167386A1 (en) * 2003-07-28 2007-07-19 Osaka Industrial Promotion Organization Remedy for cardiac failure containing ask1 inhibitor as active ingredient and method for screening the same
WO2009148896A2 (en) 2008-05-29 2009-12-10 Nuclea Biotechnologies, LLC Anti-phospho-akt antibodies
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
CA2802743C (en) 2010-07-02 2019-05-07 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors
UY34573A (es) 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
WO2016049069A1 (en) 2014-09-24 2016-03-31 Gilead Sciences, Inc. Methods of treating liver disease
MA41252A (fr) 2014-12-23 2017-10-31 Gilead Sciences Inc Formes solides d'un inhibiteur d'ask 1
JP6439050B2 (ja) 2014-12-23 2018-12-19 ギリアード サイエンシーズ， インコーポレイテッド Ａｓｋ１阻害剤を調製するプロセス

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08109197A (ja) * 1994-10-07 1996-04-30 Sumitomo Electric Ind Ltd 白血病腫瘍拒絶抗原ペプチド
ATE274053T1 (de) * 1995-11-16 2004-09-15 Novartis Pharma Gmbh Methode zur identifizierung von verbindungen die mit rac proteine kinase interagieren
US5958773A (en) * 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
GB9828375D0 (en) * 1998-12-22 1999-02-17 Janssen Pharmaceutica Nv Human akt-3
US6043090A (en) * 1999-03-23 2000-03-28 Isis Pharmaceuticals Inc. Antisense inhibition of human Akt-2 expression
EP1165784A2 (en) * 1999-03-31 2002-01-02 Curagen Corporation Nucleic acids including open reading frames encoding polypeptides; "orfx"
HUP0201663A3 (en) * 1999-06-11 2005-01-28 Gencell Inc Bridgewater Induction of vascular endothelial growth factor (vegf) by the serine/threonine protein kinase akt

Also Published As

Publication number Publication date
NO20014537L (no) 2001-10-31
HK1041288A1 (en) 2002-07-05
EP1144600B1 (en) 2008-07-30
CY1108459T1 (el) 2013-09-04
DE60039677D1 (de) 2008-09-11
PT1144600E (pt) 2008-10-10
IL141984A0 (en) 2002-03-10
AU782448B2 (en) 2005-07-28
JP2002539781A (ja) 2002-11-26
DK1144600T3 (da) 2008-11-24
SI1144600T1 (sl) 2008-12-31
HK1041288B (zh) 2008-11-07
IL145514A (en) 2010-05-17
ES2310515T3 (es) 2009-01-16
WO2000056866A2 (en) 2000-09-28
KR100700908B1 (ko) 2007-03-29
ZA200108414B (en) 2003-03-26
WO2000056866A9 (en) 2002-08-29
ATE402995T1 (de) 2008-08-15
BR0009170A (pt) 2002-04-30
JP4237945B2 (ja) 2009-03-11
CA2343074C (en) 2010-09-21
AU3880200A (en) 2000-10-09
IL145514A0 (en) 2002-06-30
KR20020011972A (ko) 2002-02-09
IL190270A (en) 2012-12-31
CA2343074A1 (en) 2000-09-28
EP1144600A2 (en) 2001-10-17
WO2000056866A3 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
CY1108459T1 (el) Ακτ-3 νουκλεϊκα οξεα, πολυπεπτιδια, και χρησεις αυτων
WO2003103589A3 (en) USE OF IL-21 IN THE TREATMENT OF CANCER AND OTHER THERAPEUTIC APPLICATIONS
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
BR9811956B1 (pt) naftiridinonas e composição farmacêutica compreendendo as mesmas.
BG100771A (en) Hematopoeic protein and ways and methods for its preparation
MX344216B (es) Productos geneticos expresados de forma diferencial en tumores y su uso.
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
WO2006018632A3 (en) Cell therapy with exo 1
DK0750672T3 (da) DNA-sekvenser for matrix-metalproteaser, deres tilvejebringelse og anvendelse
MXPA04001720A (es) Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
UA84831C2 (ru) Производные фактора коагуляции vii
DE602005021159D1 (de) Bakteriophagen- und prophagen-proteine in der krebsgentherapie
WO2001077338A3 (en) Human protein kinases and protein kinase-like enzymes
ZA95968B (en) Interferon alpha/beta binding protein its preparation and use
BR0108187A (pt) Moléculas trade e usos relacionados com as mesmas
AU2002246455A1 (en) Fusion proteins for specific treatment of cancer and auto-immune diseases
DK0980379T3 (da) Chimære oligonucleotider og deres anvendelse
WO2002006340A3 (en) Tetraspan protein and uses thereof
AU2002351596A8 (en) Mammalian simp protein, gene sequence and uses thereof in cancer therapy
WO2002034882A3 (en) Genes regulating programmed cell death
CY1113344T1 (el) Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων